OneSource receives Brazilian regulatory approval for its flagship Unit 2
10 - Apr - 2025 12:00 | 14 days ago
OneSource Specialty Pharma today announced that its flagship Unit 2 facility in Bengaluru has been granted Good Manufacturing Practices (GMP) certification by ANVISA, the Brazilian Health Regulatory Agency, following a successful regulatory inspection held in Nov 2024.
This approval marks a significant milestone in OneSource's ongoing commitment to quality and regulatory compliance. Unit 2 is OneSource's flagship site dedicated to manufacturing high quality Biologics drug substance and finished products including Drug Device Combinations (DDC) and other injectable products.
OneSource Specialty Pharma reports consolidated net loss of Rs 68.85 crore in the December 2024 quarter
29 - Jan - 2025 12:00 | 85 days ago
Net Loss of OneSource Specialty Pharma reported to Rs 68.85 crore in the quarter ended December 2024 as against net loss of Rs 130.16 crore during the previous quarter ended December 2023. Sales rose 598.38% to Rs 392.56 crore in the quarter ended December 2024 as against Rs 56.21 crore during the previous quarter ended December 2023.
OneSource Specialty Pharma reports consolidated net loss of Rs 68.85 crore in the December 2024 quarter
29 - Jan - 2025 12:00 | 85 days ago
Net Loss of OneSource Specialty Pharma reported to Rs 68.85 crore in the quarter ended December 2024 as against net loss of Rs 130.16 crore during the previous quarter ended December 2023. Sales rose 598.38% to Rs 392.56 crore in the quarter ended December 2024 as against Rs 56.21 crore during the previous quarter ended December 2023.
Shares of Onesource Specialty Pharma list in T Group
24 - Jan - 2025 12:00 | 90 days ago
The equity shares of Onesource Specialty Pharma (Scrip Code: 544292) are listed effective 24 January 2025 and admitted to dealings on the Exchange in the list of ''T'' Group Securities
OneSource receives Brazilian regulatory approval for its flagship Unit 2
10 - Apr - 2025 12:00 | 14 days ago
OneSource Specialty Pharma today announced that its flagship Unit 2 facility in Bengaluru has been granted Good Manufacturing Practices (GMP) certification by ANVISA, the Brazilian Health Regulatory Agency, following a successful regulatory inspection held in Nov 2024.
This approval marks a significant milestone in OneSource's ongoing commitment to quality and regulatory compliance. Unit 2 is OneSource's flagship site dedicated to manufacturing high quality Biologics drug substance and finished products including Drug Device Combinations (DDC) and other injectable products.
OneSource Specialty Pharma reports consolidated net loss of Rs 68.85 crore in the December 2024 quarter
29 - Jan - 2025 12:00 | 85 days ago
Net Loss of OneSource Specialty Pharma reported to Rs 68.85 crore in the quarter ended December 2024 as against net loss of Rs 130.16 crore during the previous quarter ended December 2023. Sales rose 598.38% to Rs 392.56 crore in the quarter ended December 2024 as against Rs 56.21 crore during the previous quarter ended December 2023.
Shares of Onesource Specialty Pharma list in T Group
24 - Jan - 2025 12:00 | 90 days ago
The equity shares of Onesource Specialty Pharma (Scrip Code: 544292) are listed effective 24 January 2025 and admitted to dealings on the Exchange in the list of ''T'' Group Securities
OneSource receives Brazilian regulatory approval for its flagship Unit 2
10 - Apr - 2025 12:00 | 14 days ago
OneSource Specialty Pharma today announced that its flagship Unit 2 facility in Bengaluru has been granted Good Manufacturing Practices (GMP) certification by ANVISA, the Brazilian Health Regulatory Agency, following a successful regulatory inspection held in Nov 2024.
This approval marks a significant milestone in OneSource's ongoing commitment to quality and regulatory compliance. Unit 2 is OneSource's flagship site dedicated to manufacturing high quality Biologics drug substance and finished products including Drug Device Combinations (DDC) and other injectable products.
OneSource Specialty Pharma reports consolidated net loss of Rs 68.85 crore in the December 2024 quarter
29 - Jan - 2025 12:00 | 85 days ago
Net Loss of OneSource Specialty Pharma reported to Rs 68.85 crore in the quarter ended December 2024 as against net loss of Rs 130.16 crore during the previous quarter ended December 2023. Sales rose 598.38% to Rs 392.56 crore in the quarter ended December 2024 as against Rs 56.21 crore during the previous quarter ended December 2023.
OneSource Specialty Pharma reports consolidated net loss of Rs 68.85 crore in the December 2024 quarter
29 - Jan - 2025 12:00 | 85 days ago
Net Loss of OneSource Specialty Pharma reported to Rs 68.85 crore in the quarter ended December 2024 as against net loss of Rs 130.16 crore during the previous quarter ended December 2023. Sales rose 598.38% to Rs 392.56 crore in the quarter ended December 2024 as against Rs 56.21 crore during the previous quarter ended December 2023.
Shares of Onesource Specialty Pharma list in T Group
24 - Jan - 2025 12:00 | 90 days ago
The equity shares of Onesource Specialty Pharma (Scrip Code: 544292) are listed effective 24 January 2025 and admitted to dealings on the Exchange in the list of ''T'' Group Securities